

Toll-Like Receptor 2 (*TLR-2*) Gene Polymorphisms in Type 2 Diabetes Mellitus

Zeynep Ermiş Karaali, M.D.¹, Gonca Candan, M.Sc.², Mehmet Burak Aktuğlu, M.D.¹, Mustafa Velet, M.D.¹,
Arzu Ergen, Ph.D.^{2*}

1. Department of Internal Medicine, Haseki Training and Research Hospital, University of Health Sciences, Istanbul, Turkey

2. Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey

*Corresponding Address: Istanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Molecular Medicine, Istanbul, Turkey
Email: aergen@istanbul.edu.tr

Received: 25/Sep/2017, Accepted: 13/Dec/2017

Abstract

Objective: Innate immunity factors are associated with type 2 diabetes (T2DM) and its complications. Therefore, T2DM has been suggested to be an immune-dependent disease. Elevated fasting glucose level and higher concentrations of innate immunity soluble molecules are not only related with insulin resistance, but inflammation is also an important factor in beta cell dysfunction in T2DM. Toll-like receptor 2 (*TLR-2*), which has an important role in inducing innate immune cells, is thought to have suppressive roles on immune responses in T2DM. We therefore aimed to investigate the possible role of *TLR-2* del -196-174 and Arg753Gln variants in T2DM pathogenesis.

Materials and Methods: This study was designed as a case-control study. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique was used to genotype the two variants in 100 T2DM patients and 98 age-matched controls.

Results: We found significantly higher frequencies of *TLR-2* del -196-174 DD genotype ($P=0.003$), ID genotype ($P=0.009$) and D allele ($P=0.001$) in patients compared with controls. In addition, the II genotype ($P=0.001$) and the I allele ($P=0.003$) frequencies were elevated in healthy controls. We did not find any significant differences in frequency distribution for the Arg753Gln variant in study groups.

Conclusion: We suggest that carrying the D allele of the *TLR-2* del -196-174 variant may be related as a risk factor for T2DM.

Keywords: Diabetes, Inflammation, Polymorphism, TLRs

Cell Journal(yakteh), Vol 20, No 4, Jan-Mar (Winter) 2019, Pages: 559-563

Citation: Ermiş Karaali Z, Candan G, Aktuğlu MB, Velet M, Ergen A. Toll-like receptor 2 (*TLR-2*) gene polymorphisms in Type 2 diabetes mellitus. Cell J. 2019; 20(4): 559-563. doi: 10.22074/cellj.2019.5540.

Introduction

Diabetes is defined by hyperglycemia, resulting from defects in insulin production, activation or secretion. The high prevalence of diabetes mellitus has led to morbidity and mortality (1, 2). The Turkish Diabetes Epidemiology Study II (TURDEP II) has reported the prevalence of diabetes mellitus at 13.7% in 2010 in Turkey (3-5). Previous studies have suggested that innate immune system activation and low-grade chronic inflammation are involved in the pathogenesis of type 2 diabetes mellitus (T2DM) and its complications (6-10).

Toll-like receptors (TLRs) are members of the innate immunity pathway. The role of TLRs on the pathway, which initiate a signal through the nuclear factor kappa B (NF- κ B), might have an impact on the development or progression of diabetes (11). In addition, the altered expression and/or function of *TLR-2* may be associated with progression and pathogenesis of immune-related diseases including T2DM and its complications (12-15).

Zhao et al. (16) reported that a high-glucose environment could induce the expression of *TLR-2* and *TLR-4* in retinal ganglion cells, in an attempt to elucidate the role of these genes in the etiology of diabetic retinopathy via increase in the secretion of pro-inflammatory factors. Yin et al. (17) have suggested that the role of inflammation

in β -cell dysfunction may be related through the strong link between TLRs and both inflammation and autophagy. Xiong et al. (18) has shown that the *TLR-2* Arg753Gln variant causes TLR2 signaling-incompetence by effecting to its tyrosine phosphorylation, dimerization and recruitment of Mal and MyD88. *TLR-2* del -196-174 is a 22 bp nucleotide deletion variant that alters the promoter activity of *TLR-2* (19).

The aim of this study was to investigate the possible role of *TLR-2* del -196-174 and Arg753Gln variants in the pathogenesis of T2DM in Turkish patients.

Materials and Methods

Case selection

This case-control study was designed at the Haseki Education and Training Hospital, Department of Internal medicine (Istanbul, Turkey). After obtaining written informed consent from the participants and approval from the Ethical Committee of Haseki Education and Training Hospital (No=324/2016), blood specimens were collected in tubes containing EDTA.

The patient group diagnosed with T2DM consisted of 100 patients comprising 46 females and 54 males (mean age: 73.22 ± 8.30). The control group comprised 98 randomly

selected age-matched individuals not diagnosed with T2DM (38 females and 60 males; mean age of 72.84 ± 12.98).

DNA isolation

Invitrogen PureLink was used to isolate genomic DNA from the blood samples.

Genotyping *TLR-2* variants

TLR-2 variants were genotyped by using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. A segment of the *TLR-2* gene encompassing the del -196-174 polymorphic site was amplified with specific:

F: 5'-CACGGAGGCAGCGAGAAA-3'

R: 5'-CTGGGGCCGTGCAAAGAAG-3' (20).

F: 5'-GCCTACTGGGTGGAGAACCT-3'

R: 5'-GCCACTCCAGGTAGGTCTT-3'

specific to a segment containing the Arg753Gln polymorphic site were also synthesised (21). For both variants, PCR reactions were in a total volume of 25 μ L containing 200 ng genomic DNA, 10 pmol of each primer, 200 ng dNTPs and 0.6 U Taq DNA polymerase. For the del -196-174 variant, DNA was denatured at 95°C for 2 minutes, followed by 35 cycles of 94°C for 30 seconds, 62°C for 30 seconds and 72°C for 30 seconds, and a final extension step at 72°C for 5 minutes. PCR products were examined by electrophoresis on a 3% agarose gel and the del -196-174 genotypes were identified as I/I= 286 bp, I/D= 286 bp and 264 bp, and D/D= 264 bp. For the Arg753Gln variant, DNA was denatured at 95°C for 2 minutes, followed by 35 cycles of 94°C for 30 seconds, 57°C for 30 seconds and 72°C for 30 seconds, and a final extension step at 72°C for 4 minutes. PCR products

were incubated with the *AciI* restriction enzyme at 37°C for 3 hours and the digested products were visualised by electrophoresis on a 3% agarose gel (GG=228, 75 bp, GA=266, 228, 75 bp and AA=266 bp).

Statistical analysis

SPSS 21.0 statistical software package (SPSS, Chicago, IL, USA) was used for statistical analyses. $P < 0.05$ were considered to be statistically significant. We used the χ^2 -test to evaluate the difference in *TLR-2* genotype distribution in the case and control groups. Whenever an expected cell value was less than five, Fisher's exact test was used. We compared biochemical parameters between the cases and controls by using Student's *t* test. Differences in biochemical parameters among the genotypes were investigated by using one-way ANOVA and Mann-Whitney *U* test.

Results

Demographical parameters are shown in Table 1. Distribution of *TLR-2* del -196-174 and Arg753Gln gene variants are shown in Tables 2 and 3. We did not find a significant difference in frequency distribution for the Arg753Gln variant. Nevertheless, del -196-174 DD [$P=0.003$, 95% confidence interval (CI)=0.01-0.64] and ID genotypes ($P=0.009$, 95% CI=0.06-0.73), and D allele ($P=0.001$, 95% CI=0.05-0.43) were found significantly higher frequencies in patients compared with controls. In addition, the II genotype ($P=0.001$, 95% CI=1.14-1.46) and I allele ($P=0.003$, 95% CI=1.04-1.21) frequencies were elevated in controls. Frequencies of genotypes were not in Hardy-Weinberg equilibrium (del -196-174 in patients, $P=0.0001$, del -196-174 in controls, $P=0.001$).

Table 1: Demographical parameters in study subjects

Demographical parameter	Patient n=100 Mean \pm SD	Control n=98 Mean \pm SD	P value
Age (Y)	73.22 \pm 8.30	72.84 \pm 12.98	>0.05
Gender (F/M, n)	46/54	38/60	>0.05
Fasting blood glucose (mg/dl)	179.35 \pm 81.70*	109.81 \pm 25.81	<0.001
HbA1c (mg/dl)	7.70 \pm 2.67*	4.99 \pm 1.91	<0.001
Cholesterol (mg/dl)	172.79 \pm 61.13**	130.20 \pm 45.21	0.026
Triglyceride (mg/dl)	118.15 \pm 93.62	71.67 \pm 42.43	>0.05
HDL-cholesterol (mg/dl)	36.66 \pm 14.12	34.07 \pm 6.69	>0.05
LDL-cholesterol (mg/dl)	107.50 \pm 45.98***	74.60 \pm 35.69	0.028
C-Reactive protein (mg/L)	63.43 \pm 74.72*	19.93 \pm 4.42	<0.001
Urea (mg/dl)	80.69 \pm 55.69	71.92 \pm 66.24	>0.05
Uric acid (mg/dl)	7.18 \pm 3.35****	4.54 \pm 3.59	0.006
Creatinine (mg/dl)	1.61 \pm 1.08*****	1.30 \pm 0.86	0.032
Hypertension (%)	70*	35	<0.001

F/M; Female/Male, HbA1c; Hemoglobin A1c, HDL; High density lipoprotein, LDL; Low density lipoprotein, *; $P < 0.001$, **; $P = 0.026$, ***; $P = 0.028$, ****; $P = 0.006$, and *****; $P = 0.032$.

Although we found a significant relationship based on genotype frequencies, there were no relationship between *TLR-2* del -196-174 genotypes and clinical parameters except hypertension in patients. Carrying the II genotype [$P=0.034$, $\chi^2=4.48$, odds ratio (OR)=2.86, 95% CI=1.06-7.73] and the I allele ($P=0.023$, $\chi^2=5.14$, OR=3.99, 95% CI=1.13-14.00) might be a risk factor for hypertension in diabetes.

In addition, the DD genotype ($P=0.023$, $\chi^2=5.14$, OR=1.77, 95% CI=1.11-9.23) and the D allele ($P=0.034$, $\chi^2=4.48$, OR=1.45, 95% CI=1.06-4.16) might have a protective role against hypertension (Table 4). In addition, we observed that HbA1c values were lower in patients with hypertension (7.07 ± 2.24 mg/dl) than non-hypertension (9.10 ± 3.03 mg/dl) patients ($P=0.002$, 95% CI=1.74-3.32).

Table 2: Distribution of *TLR-2* del -196-174 variant genotypes

<i>TLR-2</i> del -196-174 polymorphism	Patient n=100 n (%)	Control n=98 n (%)	P value
II	74 (74%)	94 (95.9%)*	0.001
DD	12 (12%)**	1 (1%)	0.003
ID	14 (14%***)	3 (3.1%)	0.009
I	162 (81%)	191 (95.5%)**	0.003
D	38 (19%)*	5 (4.5%)	0.001

DD; deletion/deletion genotype, ID; Insertion/deletion genotype, D; Deletion allele, I; Insertion allele, II; Insertion/insertion genotype, *; $P=0.001$, **; $P=0.003$, and ***; $P=0.009$.

Table 3: Distribution of *TLR-2* Arg753Gln variant genotypes

<i>TLR-2</i> Arg753Gln polymorphism	Patient n=100 n (%)	Control n=98 n (%)	P value
GG	99 (99%)	98 (100%)	>0.05
AA	-	-	-
GA	1 (1%)	-	-
G	199 (99.5%)	196 (100%)	>0.05
A	1 (0.5%)	-	-

Table 4: Comparison of del -196-174 genotypes and demographic parameters in T2DM patients

Demographic parameters	del -196-174 genotypes			del -196-174 alleles	
	DD	II	ID	D	I
Fasting blood glucose (mg/dl)	197.50 \pm 79.66	175.09 \pm 86.43	186.29 \pm 55.19	191.46 \pm 66.40	176.88 \pm 82.10
HbA1c (mg/dl)	7.29 \pm 3.19	7.72 \pm 2.37	8.12 \pm 3.89	7.64 \pm 3.42	7.78 \pm 2.58
Cholesterol (mg/dl)	182.00 \pm 103.26	167.28 \pm 58.88	191.17 \pm 56.16	188.11 \pm 68.25	171.90 \pm 58.23
Triglyceride (mg/dl)	105.40 \pm 59.55	117.10 \pm 91.14	134.00 \pm 85.37	121.00 \pm 104.69	119.92 \pm 89.24
HDL-cholesterol (mg/dl)	40.65 \pm 16.65	33.96 \pm 12.64	45.93 \pm 17.00	44.17 \pm 16.03	36.27 \pm 14.11
LDL-cholesterol (mg/dl)	106.33 \pm 73.07	105.08 \pm 43.99	118.17 \pm 48.64	114.22 \pm 53.37	107.61 \pm 44.38
C-Reactive protein (mg/L)	76.58 \pm 29.55	64.84 \pm 8.79	45.93 \pm 15.43	59.41 \pm 15.55	61.73 \pm 7.78
Urea (mg/dl)	76.30 \pm 57.62	78.51 \pm 55.61	98.61 \pm 55.95	86.97 \pm 56.68	81.38 \pm 55.74
Uric acid (mg/dl)	6.74 \pm 1.95	7.09 \pm 3.52	8.19 \pm 3.86	7.42 \pm 2.97	7.26 \pm 3.55
Creatinine (mg/dl)	1.43 \pm 1.04	1.55 \pm 1.05	2.03 \pm 1.21	1.77 \pm 1.16	1.63 \pm 1.09
Hypertension (%)	41.7**	75.8*	63.6	52.2*	74**

DD; Deletion/deletion genotype, ID; Insertion/deletion genotype, D; Deletion allele, I; Insertion allele, II; Insertion/insertion genotype, HbA1c; Hemoglobin A1c, HDL; High density lipoprotein, LDL; Low density lipoprotein, *; $P=0.034$, and **; $P=0.023$.

Discussion

Toll-like receptors are surface proteins on eukaryotic cells to detect and respond to microbial antigens (22). There is evidence for TLRs, especially TLR-2 and TLR-4, that they alter proinflammatory and host defense functions of human neutrophils (23). Expression of *TLR-4* and its ligand confer systemic insulin resistance in condition of elevated free fatty acids in blood (24).

TLR-2 is reported to have an important role in the pathogenesis of T2DM in recent studies. For instance, Dasu et al. have shown that *TLR-2* expression is increased in patients with T2DM and contributes to the proinflammatory state (25). Devaraj et al. (26) have reported that *TLR-2* and *TLR-4* ligand levels are increased in type 1 diabetes, resulting in the proinflammatory state of the disease in concert with hyperglycaemia, and thus accounting for the increase in *TLR-2* and *TLR-4* activity.

Huang et al. (27) reported that SNP rs1898830 in *TLR-2* is associated with T2DM risk in the Chinese population. They found that the AA genotype was associated with the secretion of pro-inflammatory cytokines and chemokines, which in turn promote inflammation in some tissues, thus resulting in insulin resistance and ultimately T2DM development (28-30).

Maldonado-Bernal et al. (31) observed that the *TLR-2* R753Q variant was very low in frequency and insignificantly less frequent in T2DM patients than in healthy donors. Wifi et al. (32) found no statistical difference in the distribution of *TLR-2* -1350T/C genotypes in T2DM. In the present study, we have found a significant association for *TLR-2* del -196-174 but not for the Arg753Gln gene variant in Turkish T2DM patients. We also observed an association with hypertension, however, to clarify the effect of del -196-174 genotypes on hypertension, study of patients with only hypertension will be essential.

Conclusion

Our results demonstrate that the *TLR-2* is associated with increased T2DM risk. Further investigations with larger scale sample sizes are needed to confirm our findings and functional studies will be required to unravel the mechanism underlying this association.

Acknowledgements

There is no financial support and conflict of interest in this study.

Authors' Contributions

Z.E.K.; Sample collection, clinical evaluation, drafting the manuscript. G.C.; DNA isolation and PCR-RFLP. M.B.A., M.V.; Patient selection and obtaining permission. A.E.; Study design, statistical analysis,

responsible for overall supervision. All authors read and approved the final manuscript.

References

1. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*. 2010; 33(Suppl 1): S62-S69.
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract*. 2010; 87(1): 4-14.
3. Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dincçag N, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. *Eur J Epidemiol*. 2013; 28(2): 169-180.
4. Abstracts of the 46th General Assembly of the European Association for the Study of Diabetes (EASD). Stockholm, Sweden. September 20-24, 2010. *Diabetologia*. 2010; 53 (Suppl 1): S7-S533.
5. Malhan S, Öksüz E, Babineaux SM, Ertekin A, Palmer JP. Assessment of the direct medical costs of type 2 diabetes mellitus and its complications in Turkey. *Turk Journal of Endocrinology and Metabolism*. 2014; 2: 39-43.
6. Biondi-Zoccai GG, Abbate A, Liuzzo G, Biasucci LM. Atherothrombosis, inflammation, and diabetes. *J Am Coll Cardiol*. 2003; 41(7): 1071-1077.
7. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? *Diabetologia*. 2005; 48(6): 1038-1050.
8. Jin C, Henao-Mejia J, Flavell RA. Innate immune receptors: key regulators of metabolic disease progression. *Cell Metab*. 2013; 17(6): 873-882.
9. Cruz M, Maldonado-Bernal C, Mondragon-Gonzalez R, Sanchez-Barrera R, Wachter NH, Carvajal-Sandoval G, et al. Glycine treatment decreases proinflammatory cytokines and increases interferon-gamma in patients with type 2 diabetes. *J Endocrinol Invest*. 2008; 31(8): 694-699.
10. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. *Diabetes Care*. 2004; 27(3): 813-823.
11. Wong FS, Wen L. Toll-like receptors and diabetes. *Ann N Y Acad Sci*. 2008; 1150: 123-132.
12. Yu JT, Mou SM, Wang LZ, Mao CX, Tan L. Toll-like receptor 2 -196 to -174 del polymorphism influences the susceptibility of Han Chinese people to Alzheimer's disease. *J Neuroinflammation*. 2011; 8: 136.
13. Nischalke HD, Coenen M, Berger C, Aldenhoff K, Muller T, Berg T, et al. The toll-like receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. *Int J Cancer*. 2012; 130(6): 1470-1475.
14. Zhu L, Yuan H, Jiang T, Wang R, Ma H, Zhang S. Association of TLR2 and TLR4 polymorphisms with risk of cancer: a meta-analysis. *PLoS One*. 2013; 8(12): e82858.
15. Sepehri Z, Kiani Z, Nasiri AA, Kohan F. Toll-like receptor 2 and type 2 diabetes. *Cell Mol Biol Lett*. 2016; 28: 21: 2.
16. Zhao M, Li CH, Liu YL. Toll-like receptor (TLR)-2/4 expression in retinal ganglion cells in a high-glucose environment and its implications. *Genet Mol Res*. 2016; 15(2).
17. Yin J, Peng Y, Wu J, Wang Y, Yao L. Toll-like receptor 2/4 links to free fatty acid-induced inflammation and β -cell dysfunction. *J Leukoc Biol*. 2014; 95(1): 47-52.
18. Xiong Y, Song C, Snyder GA, Sundberg EJ, Medvedev AE. R753Q polymorphism inhibits Toll-like receptor (TLR) 2 tyrosine phosphorylation, dimerization with TLR6, and recruitment of myeloid differentiation primary response protein 88. *J Biol Chem*. 2012; 287(45): 38327-38337.
19. Mandal RK, George GP, Mittal RD. Association of Toll-like receptor (TLR) 2, 3 and 9 genes polymorphism with prostate cancer risk in North Indian population. *Mol Biol Rep*. 2012; 39(7): 7263-7269.
20. Tahara T, Arisawa T, Wang F, Shibata T, Nakamura M, Sakata M, et al. Toll-like receptor 2 -196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer. *Cancer Sci*. 2007; 98(11): 1790-1794.
21. Karaca NE, Gulez N, Aksu G, Azarsiz E, Kutukculer N. Does OM-85 bv prophylaxis trigger autoimmunity in IgA deficient children? *Int Immunopharmacol*. 2011; 11(11): 1747-1751.
22. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. *Biochem Biophys Res Commun*. 2009; 388(4): 621-625.
23. Sabroe I, Dower SK, Whyte MK. The role of Toll-like receptors in the regulation of neutrophil migration, activation, and apoptosis. *Clin Infect Dis*. 2005; 41(Suppl 7): S421-S426.

24. Zu L, He J, Jiang H, Xu C, Pu S, Xu G. Bacterial endotoxin stimulates adipose lipolysis via toll-like receptor 4 and extracellular signal-regulated kinase pathway. *J Biol Chem*. 2009; 284(9): 5915-5926.
25. Dasu MR, Devaraj S, Park S, Jialal I. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. *Diabetes Care*. 2010; 33(4): 861-868.
26. Devaraj S, Dasu MR, Park SH, Jialal I. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. *Diabetologia*. 2009; 52(8):1665-1668.
27. Huang WH, Nie LH, Zhang LJ, Jing LP, Dong F, Wang M, et al. Association of TLR2 and TLR4 non-missense single nucleotide polymorphisms with type 2 diabetes risk in a southern Chinese population: a case-control study. *Genet Mol Res*. 2014;14 (3): 8694-8705.
28. Ehses JA, Meier DT, Wueest S, Rytka J, Boller S, Wielinga PY, et al. Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. *Diabetologia*. 2010; 53(8): 1795-1806.
29. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. *Nat Med*. 2005; 11(2): 183-190.
30. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. *Nat Rev Immunol*. 2011; 11(2): 98-107.
31. Maldonado-Bernal C, Trejo-de la OA, Sánchez-Contreras ME, Wachter-Rodarte N, Torres J, Cruz M. Low frequency of Toll-like receptors 2 and 4 gene polymorphisms in Mexican patients and their association with type 2 diabetes. *Int J Immunogenet*. 2011; 38(6): 519-523.
32. Wafi MA, Assem M, Elsherif RH, El-Azab HA, Saif A. Toll-like receptors-2 and -9 (TLR2 and TLR9) gene polymorphism in patients with type 2 diabetes and diabetic foot. *Medicine (Baltimore)*. 2017; 96(17): e6760.

Archive of SID